Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.26 USD

51.26
3,013,431

-1.59 (-3.01%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $51.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance

Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.

    Company News For Jan 30, 2018

    Companies In The News are: LMT,DPS,CYOU,ABLYF,SNY,NVO

      Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B

      Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.

        Sanghamitra Saha headshot

        Biotech ETF (XBI) Hits New 52-Week High

        This biotech ETF hit a new 52-week high. Are more gains in store for this fund?

          Swarup Gupta headshot

          Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ

          The government shutdown in the United States guided stocks across Europe and Asia last week.

            Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat

            Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.

              Tirthankar Chakraborty headshot

              Play Biotech Buyout Frenzy With These 2 Solid Funds

              More deals are expected to be signed in the biotech space, courtesy of the tax reform bill that allows companies to repatriate cash piled overseas

                Stock Market News For Jan 23, 2018

                Major benchmarks hit record highs on Monday after the Senate gave its consent to pass a Bill that ends the current government shutdown.

                  Regeneron's Dupixent Receives MHLW Nod for Label Expansion

                  Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

                    Tirthankar Chakraborty headshot

                    Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks

                    More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.

                      Arpita Dutt headshot

                      Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?

                      Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?

                        Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips

                        Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.

                          Arpita Dutt headshot

                          Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?

                          Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.

                            CES 2018 Promises a Thrilling Year for Gaming Enthusiasts

                            During CES 2018, a number of companies displayed some extravagant products which are set to change the gaming experience entirely this year.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

                              Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

                                Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes

                                Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.

                                  Emergent Down on '18 View, Posts Preliminary '17 Results

                                  Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.

                                    AbbVie's Upadacitinib Gains Breakthrough Therapy Designation

                                    AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.

                                      Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab

                                      Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.

                                        Alnylam, Sanofi Announce Restructuring Deal for RNAi Products

                                        Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.

                                          5 Reasons to Pick Emergent as an Investment-Worthy Stock

                                          Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.

                                            Arpita Dutt headshot

                                            3 Biotech and Pharma Stocks with FDA Catalysts this January

                                            2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.

                                              Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

                                              Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.

                                                BioMarin's (BMRN) Gene Therapy Enters First Phase III Study

                                                BioMarin (BMRN) commences the first phase III study to evaluate the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.

                                                  Why is Alnylam's (ALNY) Stock Up More Than 200% This Year?

                                                  Alnylam's (ALNY) share price has increased year to date based on impressive progress of its pipeline candidates.